Point72 Asset Management L.P. grew its stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) by 10.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 65,809 shares of the company’s stock after purchasing an additional 6,358 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.42% of BioXcel Therapeutics worth $605,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BTAI. BlackRock Inc. acquired a new position in shares of BioXcel Therapeutics in the second quarter valued at approximately $137,000. Millennium Management LLC acquired a new position in BioXcel Therapeutics during the first quarter worth $316,000. Barclays PLC acquired a new position in BioXcel Therapeutics during the first quarter worth $6,331,000. Finally, California Public Employees Retirement System acquired a new position in BioXcel Therapeutics during the first quarter worth $3,362,000. 23.81% of the stock is owned by hedge funds and other institutional investors.

BTAI has been the subject of several recent research reports. Zacks Investment Research upgraded shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a report on Tuesday, August 14th. Canaccord Genuity restated a “buy” rating and set a $21.00 target price on shares of BioXcel Therapeutics in a report on Friday, August 10th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of BioXcel Therapeutics in a report on Wednesday, August 1st. Six analysts have rated the stock with a buy rating, BioXcel Therapeutics currently has an average rating of “Buy” and an average price target of $18.67.

Shares of BTAI opened at $7.54 on Monday. BioXcel Therapeutics Inc has a 12 month low of $6.76 and a 12 month high of $14.79.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Wednesday, August 8th. The company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.13. equities analysts forecast that BioXcel Therapeutics Inc will post -1.12 earnings per share for the current fiscal year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

See Also: Should You Consider an Index Fund?

Want to see what other hedge funds are holding BTAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioXcel Therapeutics Inc (NASDAQ:BTAI).

Institutional Ownership by Quarter for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.